

*Updated: March 2008*

## CURRICULUM VITAE

**NAME:** G. Edward Stewart II, M.D.

**OFFICE ADDRESS:** Allergy and Asthma Care of Florida  
1500 SE Magnolia Extension, Suite 203  
Ocala, FL 34471

**CLINICAL RESEARCH  
OFFICE ADDRESS:** Allergy and Asthma Care of Florida  
Clinical Research Division  
1500 SE Magnolia Extension, Suite 204  
Ocala, FL 34471

**TELEPHONE:** (352) 622-1126 (office)  
(352) 622-2391 (fax)  
(352) 629-2223 (research office)  
(352) 401-3776 (research fax)  
1-888-629-2228 (toll-free research office)

### **PROFESSIONAL EDUCATION:**

University of Tennessee College of Medicine, Memphis, Tennessee, M.D., 1988.

University of Tennessee College of Pharmacy, Memphis, Tennessee, B.S. Pharmacy, 1979.

Lambuth College, Jackson, Tennessee, B.S., 1977.

### **PROFESSIONAL EXPERIENCE:**

Physician, Private Practice, Allergy and Asthma Care of Florida, 1800 SE 17<sup>th</sup> Street, Office 300, Ocala, Florida 34471, July 1994 to Present.

Advanced Subspecialty Resident, Diagnostic and Clinical Laboratory Immunology, University of South Florida, Tampa, Florida, July 1993 to June 1994.

Advanced Subspecialty Resident, Division of Allergy and Clinical Immunology, University of South Florida, Tampa, Florida, July 1991 to June 1993.

Resident, Internal Medicine, University of Tennessee, Baptist Memorial Hospital, Memphis, Tennessee, June 1988 to June 1991.

#### **HOSPITAL SERVICE:**

Munroe Regional Medical Center: 1500 SW 1<sup>st</sup> Avenue, Ocala, Florida, 34471, Staff and Consulting Privileges, 1994 to Present.

Ocala Regional Medical Center: 1431 SW 1<sup>st</sup> Avenue, Ocala, Florida, 34471, Staff and Consulting Privileges, 1994 to Present.

#### **UNIVERSITY SERVICE:**

Clinical Associate Professor of Medicine, College of Medicine, University of South Florida, Tampa, Florida, July 2006 to Present.

Clinical Assistant Professor of Medicine, College of Medicine, University of South Florida, Tampa, Florida, January 5, 1999 to July 2006.

#### **LICENSURE:**

Florida, ME 0060635

Tennessee, MD020009 (retired)

Tennessee, Doctor of Pharmacy C005102 (inactive)

#### **CERTIFICATION:**

American Board of Allergy and Immunology, October 11, 1993.

American Board of Internal Medicine, September 25, 1991.

#### **PROFESSIONAL MEMBERSHIP:**

Fellow, American Academy of Allergy, Asthma and Immunology

Fellow, American College of Allergy, Asthma, and Immunology

American Medical Association

Associates of Clinical Research Professionals

Southeastern Allergy Association, Incorporated

Florida Allergy, Asthma & Immunology Society

Florida Medical Association

Marion County Medical Society

**EDITORIAL BOARD MEMBERSHIP:**

Mometasone Editorial Board, Key Pharmaceuticals, 1999.

**COMMITTEE MEMBERSHIP:**

Pharmacotherapeutics Committee of the American Academy of Allergy and Immunology.

**OFFICES HELD:**

President, Florida Allergy, Asthma and Immunology Society, 2002 to 2003.

President-Elect, Florida Allergy, Asthma and Immunology Society, 2001 to 2002.

Respiratory National Visiting Professor Program, Aventis Pharmaceuticals, February 2001 to February 2002.

Treasurer, Florida Allergy, Asthma and Immunology Society, 2000 to 2001.

Secretary, Florida Allergy, Asthma and Immunology Society, 1999 to 2000.

Chairman, Legislative Liaison Committee, Florida Allergy, Asthma and Immunology Society, 1998 to 2000.

Chairman, North Central Florida Allergy Journal Club, 1998 to Present.

Library Committee, Munroe Regional Medical Center, 1995 to 1996.

Co-Chairman, Fellow-In-Training Committee, American Academy of Allergy, Asthma & Immunology, March 1992 to March 1994.

**HONORS:**

Member, "Strathmore's Who's Who", 2002 - 2003.

Member, "The Best Doctors in America", 2001 - 2002.

Member, "The Best Doctors in America", 1998.

Member, "The Marquis Who's Who in the South and Southeast Twenty Fifth Edition", 1997-1998.

Member, "Cambridge Who's Who Registry of Business Leaders, 1996-1997.

Faculty Member, Southern Regional Advisory Board, Zeneca Pharmaceuticals, 1996.

Chief Resident, Division of Allergy and Clinical Immunology, University of South Florida, Tampa, Florida, January 1992 to June 1993.

Outstanding Clinical Study, "Comparison of Oral Pulse Methotrexate with Placebo in the Treatment of Severe Glucocorticosteroid Dependent Asthma." Florida Chapter of the American College of Physicians, October 1993.

Co-winner, Baptist Memorial Hospital Clinical Vignette Competition, "Listeria Monocytogenes Meningitis in a Non-Immunocompromised Host", September 1988.

#### **FACULTY FOR POST-GRADUATE SEMINARS AND SYMPOSIA:**

Presentation: "Managing Drug Allergy", Presentation for Allied Health Section of Florida Asthma, Allergy, & Immunology Social Annual Meeting, Aboard H.M.S. Fantasy, Nassau, Bahamas, June 18, 1999.

Faculty, Florida Allergy, Asthma and Immunology Society Allied Health Section Annual Meeting, HMS Fantasy, Nassau, Bahamas, June 17 to 20, 1999, "Managing Drug Allergies".

Faculty, Florida Allergy, Asthma and Immunology Society Allied Health Section Annual Meeting, Ft. Meyers, Florida, June 12 to 14, 1998, "What Patients Need to Know About Sinusitis".

Faculty, Florida Academy of Physician's Assistants Annual Meeting, St. Petersburg, Florida, August 7, 1996, "Management of Allergic Rhinitis and Sinusitis".

Faculty, New Directions in the Management of Asthma and Allergy, Sponsored by University of Wisconsin Medical School in Association with the National Institute of Allergy and Infectious Diseases, Tarpon Springs, Florida, May 11, 1996.

Faculty, Southern Regional Advisory Board, Zeneca Pharmaceuticals, Atlanta, GA, March 1-2, 1996.

Panelist, Fellows-In-Training Program: 51<sup>st</sup> Annual Meeting of the American Academy of Allergy and Immunology, New York, NY, February 24, 1995.

Speaker, Fellows-In-Training Program: 51<sup>st</sup> Annual Meeting of the American Academy of Allergy and Immunology, New York, NY, February 24, 1995, "How to Prepare for Allergy and Immunology Certifying Examination".

Speaker, Workshop Seminar: 50<sup>th</sup> Annual Meeting of the American Academy of Allergy and Immunology, Anaheim, California, March 5, 1994, “The Zen of Personal Computing for the Novice - Discos Through Floppies”.

Post-graduate Conference: Clinical Allergy & Immunology for the Practicing Physician. Lecturer, Sponsored by the American Academy of Allergy and Immunology and Hosted by the University of South Florida College of Medicine, Division of Allergy and Immunology, Lake Buena Vista, Florida, December 3, 1993, “Allergic Reactions to Stinging Insects”.

Orlando Veterans Administration Hospital, Orlando, Florida, August 25, 1993, “An Update on the Outpatient Management of Asthma”.

Post-graduate Conference: The Problem of the “Sick” Building Facts & Implications. Lecturer, Sponsored by the American Academy of Allergy and Immunology and Hosted by the University of South Florida College of Medicine, Division of Allergy and Immunology, Lake Buena Vista, Florida, December 4, 1992, “Case Report: Sick Building Syndrome”.

Post-graduate Conference: Occupational Lung Disease. Lecturer, Sponsored by the American College of Chest Physicians and Hosted by the University of South Florida College of Medicine, Division of Pulmonary Medicine, Wesley Chapel, Florida, June 5, 1992, “Current Concepts of Occupational Allergy and Asthma: Isocyanates, Wood Dusts, and Metallic Salts”.

Post Graduate Conference: “Seasonal Variation in Group I Mite Allergen Levels in Homes in Tampa, Florida”, Eastern Allergy Conference/Southwest Allergy Forum Annual Meeting, New Orleans, Louisiana, May 1, 1992.

## **BIBLIOGRAPHY:**

### **MONOGRAPHS:**

Lockey RF, Maxwell LS, **Stewart GE**: Florida’s Poisonous Plants, Snakes, Insects. 3<sup>rd</sup> Edition, 1992.

### **EXPERIMENTAL PAPERS:**

**Stewart GE**, Diaz JD, Lockey RF, Seleznick MJ, Trudeau WL, Ledford DK: Comparison of Oral Pulse Methotrexate with Placebo in the Treatment of Severe Glucocorticoid-Dependent Asthma. *J Allergy Clin Immunol* 1994;94:482-9.

## REVIEWS, INVITED ARTICLES AND EDITORIALS:

**Stewart GE:** Submitted for Publication. Histopathology of Chronic Urticaria. Clinical Reviews in Allergy and Immunology. 2002.

Ring J, Hein R, Gauger A, Bronsky E, Miller B, and the Desloratadine Study Group (**Stewart GE**): Once-daily Desloratadine Improves the Signs and Symptoms of Chronic Idiopathic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Study. International Journal of Dermatology. 2001.

Meltzer E., Baena-Cagnani C., Chervinsky P., **Stewart GE**, Bronsky E., Lutsky B.: Submitted for Publication. Once Daily Mometasone Furoate by Dry Powder Inhaler for the Treatment of Children with Moderate Persistent Asthma. 2000.

Kemp JP., **Stewart GE**, Ruff ME, Murray JJ, Harrison JE, : Submitted for Publication. Mometasone Furoate Administered Once-Daily is as Effective as Twice-Daily for Treatment of Patients with Mild to Moderate Persistent Asthma. 1999.

Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, Galant SP, Grossman J, Hampel FC, Ratner PH, Ruff ME, Schenkel EJ, Segal AT, Segall N, **Stewart GE**, Tripathy I, Skoner DP, Anolik R, Dockhorn RJ, van Bavel J, Mesarina-Wicki B, Nolop KB: Submitted for Publication. Dose-Ranging Study of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in Children with Seasonal Allergic Rhinitis. J. Allergy Clin Immunol, 1997.

**Stewart GE**, Lockey RF: Applications for IV Immunoglobulin Therapy. Contemporary Internal Medicine 7:71-74, 1995.

**Stewart GE**, Altenburger KM: Common Allergic Problems in the Outpatient Setting. Florida Family Physician, XLV:13, 1995.

**Stewart GE:** Letter from the Co-Chairs. Fellows-In-Training Newsletter, AAAI, Vol. 13, March 1994.

Peebles RS, **Stewart GE:** Letter from the Co-Chairs. Fellows-In-Training Newsletter, AAAI, Vol. 13, December 1993.

**Stewart GE**, Lockey RF: Letter to the Editor. J Allergy Clin Immunol 92:498, 1993.

**Stewart GE:** Letter from the Co-Chairs. Fellows-In-Training Newsletter, AAAI, Vol. 11, June 1993.

**Stewart GE:** Letter from the Co-Chairs. Fellows-In-Training Newsletter, AAAI, Vol. 11, March 1993.

**Stewart GE**, Wright DN: Letter from the Co-Chairs. Fellows-In-Training Newsletter, AAAI, Vol. 10, November 1992.

**Stewart GE**, Lockey RF: Editorial: Systemic Reactions From Allergen Immunotherapy. J Allergy Clin Immunol 90:312-318, 1992.

**Stewart GE**, Wright DN: Letter from the Co-Chairs. Fellows-In-Training Newsletter, AAAI, Vol 9, July 1992.

**Stewart GE**: Carbon Monoxide Poisoning and Delayed Neurologic Sequelae. Tennessee Forensic Headliner 10:1988.

#### **ABSTRACTS: (\*PRESENTED)**

**Stewart GE**, Calderon E, Szentivanyi A, Lockey RF: IgE Decreases Endothelin-1 (ET-1) Production in A549 Pulmonary Epithelial Cells. J Allergy Clin Immunol 93(1):492, 1994.

**Stewart GE**, Fernandez-Caldas E, Trudeau WL, Swanson MC, Ledford DK, Lockey RF: Seasonal Variation of Group I Mite Allergen Levels in Homes in Tampa, Florida. Allergy Proc. 14:32, 1993.

**Stewart GE**, Trudeau WL, Fernandez-Caldas E, Lockey RF: Immunochemical Characterization of Myrica Cerifera (Bayberry) Allergens. J Allergy Clin Immunol 91(1):273, 1993.

Ledford DK, **Stewart GE**, Diaz JD, Trudeau WL, Seleznick M, Lockey RF: Comparison of Oral Pulse Methotrexate with Placebo in Treatment of Severe Glucocorticosteroid Dependent Asthma. J Allergy Clin Immunol 91(1):168, 1993.

Fernandez-Caldas E, Trudeau WL, **Stewart GE**, Swanson MC, Stanaland BE, Ledford DK, Lockey RF: Seasonal Variations of Group I Mite Allergens in Homes in Tampa, Florida. J Allergy Clin Immunol 93(1):327, 1993.

#### **EXHIBITS:**

**Stewart GE**, Diaz JD, Lockey RF, Seleznick MJ, Trudeau WL, Ledford DK: Comparison of Oral Pulse Methotrexate with Placebo in Treatment of Severe Glucocorticosteroid Dependent Asthma. Florida Medical Association Annual Meeting, May, 1993, (Outstanding Clinical Study Award).

#### **CLINICAL RESEARCH:**

Principal Investigator, "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Impact on Health-Related Quality of Life of levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 Years of Age and Older with Seasonal Allergic Rhinitis", UCB, Inc., A00430, Allergy & Asthma Care of Florida, Ocala, Florida, 2008.

Principal Investigator: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110 mcg QD in Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis”, GlaxoSmith Kline, FFR101782, Allergy & Asthma Care of Florida, Ocala, Florida, 2008.

Principal Investigator: “A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 100 mcg Twice Daily compared to Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy”, GlaxoSmithKline, FFA109687, Allergy & Asthma Care of Florida, Ocala, Florida, 2008.

Principal Investigator: “A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250 mcg Twice Daily compared to Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy”, GlaxoSmithKline, FFA109685, Allergy & Asthma Care of Florida, Ocala, Florida, 2008.

Principal Investigator: “A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500 mcg Twice Daily compared to Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy”, GlaxoSmithKline, FFA109684, Allergy & Asthma Care of Florida, Ocala, Florida, 2008.

Principal Investigator: “A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 mg o.d.) In patients with Chronic Obstructive Pulmonary Disease”, Novartis, CQAB149B2346, Allergy & Asthma Care of Florida, Ocala, Florida, 2008.

Principal Investigator: “A Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol-HFA, Versus the Active Control, Proventil®-HFA, in Adult and Adolescent Asthmatic Patients”, API-A004-CLN-C, Amphastar Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2007

Principal Investigator: “Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis”, MedPointe Pharmaceuticals, MP436, Allergy & Asthma Care of Florida, Ocala, Florida, 2007

Principal Investigator: “Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Patients with Perennial Allergic Rhinitis”, MP435, MedPointe Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2007

Principal Investigator: “Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis”, P04824, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2007

Principal Investigator: “Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis”, PO5067, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2007

Sub-Investigator: “Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease - A 52-Week, Multicenter, Double-blind Study with 500 mcg Roflumilast Once Daily versus Placebo” - HERMES STUDY, BY217/M2-125, ALTANA Pharma, Allergy & Asthma Care of Florida, Ocala, Florida, 2006

Principal Investigator: “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (Flutiform™ 100/10 ug twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Placebo or Fluticasone (100ug twice daily) and Formoterol (10ug twice daily) Alone in Adult Patients with Asthma”, SKY2028-3-001, SkyePharma AG, Allergy & Asthma Care of Florida, Ocala, Florida, 2006

Principal Investigator: “A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel -Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma which is also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity”, 336-00, Merck & Co., Inc., Allergy & Asthma Care of Florida, Ocala, Florida, 2006

Principal Investigator: “A Prospective, Randomized, Double-Blind Study of the Efficacy of Xolair® in Atopic Asthmatics with Good Lung Capacity who Remain Difficult to Treat (EXACT)”, Q2982g, Genentech, Inc., Allergy & Asthma Care of Florida, Ocala, Florida, 2006

Principal Investigator: “A Phase IIIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair® in Subjects with Moderate to Severe Persistent Asthma who are inadequately controlled with Advair 500/50 BID”, Q3662g, Genentech, Inc., Allergy & Asthma Care of Florida, Ocala, Florida, 2006

Principal Investigator: “A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200 mcg QD versus Montelukast 10 mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis who are Receiving ADVAIR DISKUS 100/50 mcg BID or Placebo BID”, ADA103575, GlaxoSmithKline, Allergy & Asthma Care of Florida, Ocala, Florida, 2005

Principal Investigator: “Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip”, P04258, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2005

Principal Investigator: “Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethaone Dipropionate (Qvar®) Verses Placebo by Breath Operated and Metered Dose Inhalers in Mild to Moderate Asthmatic Children”, IXR-302-25-197, IVAX Research, Inc., Allergy & Asthma Care of Florida, Ocala, Florida, 2005

Principal Investigator: “An Efficacy and Safety Study of SYMBICORT pMDI 2 x 160/4.5ug BID and SYMBICORT pMDI x 80/4.5ug BID Compared to Formoterol Turbohaler 2 x 4.5ug BID and Placebo in Patients with COPD”, D5899C00002, AstraZeneca, Allergy & Asthma Care of Florida, Ocala, Florida, 2004

Principal Investigator: “An Epidemiology Study of Xolair (Omalizumab) Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)”, Q2948q, Genentech/Novartis, Allergy & Asthma Care of Florida, Ocala, Florida, 2004

Principal Investigator: “Efficacy and Safety Evaluation of Nasacort AQ 110ug QD, Followed By a Six-Month Open-Label Safety in children with Perennial Allergic Rhinitis”, XRG-5029C/3502, Aventis Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2004

Principal Investigator: “Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200ug, 100ug, or 25ug,once daily) in the treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11Years of Age”, BY9010/M1-403, ALTANA Pharma, Allergy & Asthma Care of Florida, Ocala, Florida, 2004

Principal Investigator: “Efficacy and Safety of 200mcg QD or 200mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis”, PO2692, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2004.

Principal Investigator: “A Four-Week, Double-Blind, Placebo-Controlled Exploratory Evaluation of FEV 1.0 Changes and Safety of ONO-6126 in Patients with Chronic Obstructive Pulmonary Disease (COPD)”, ONO-6126POU011, ONO Pharma USA, Inc., Allergy & Asthma Care of Florida, Ocala, Florida, 2004.

Principal Investigator: “A Randomized, Controlled Study of Roflumilast (250mcg and 500mcg) Versus Placebo in Patients with Asthma. A 24-Week, Multicenter, Multinational, Double-Blind Parallel Group Clinical Study”, BY217/M2-023 (FLASH Trial) , ALTANA Pharma, Allergy & Asthma Care of Florida, Ocala, Florida, 2004.

Principal Investigator: “A Fifty-two Week, Randomized, Double-Blind, Single-Dummy, Parallel Group, Multicenter, Phase III Study Comparing the Longe-Term Safety SYMBICORT pMDI 160/4.5 ug x 4 Actuations Twice Daily to SYMBICORT pMDI 160/4.5ug x 2 Actuations Twice Daily and Budesonide HFA pMDI 160ug x 4 Actuations Twice Daily in Adult and Adolescent Subjects with Asthma”, SD-039-0728, AstraZeneca, Allergy & Asthma Care of Florida, Ocala, Florida, 2003.

Principal Investigator: “An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Albuterol HFA with Counter in Asthma or COPD Subjects at Least 4 Years of Age”, SBO30003, GlaxoSmithKline, Allergy & Asthma Care of Florida,

Ocala, Florida, 2003.

Principal Investigator: “An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age”, SAS30033, GlaxoSmithKline, Allergy & Asthma Care of Florida, Ocala, Florida, 2003.

Principal Investigator: “A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler® and the New Version of Pulmicort Turbuhaler® in Asthmatic Adults Currently Treated with Inhaled Steroids”, SD-004-0620, AstraZeneca, Allergy & Asthma Care of Florida, Ocala, Florida, 2003.

Principal Investigator: “A Placebo-Controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbuhaler® and the New Version of Pulmicort Turbuhaler® in Asthmatic Children and Adolescents”, SD-004-0726, AstraZeneca, Allergy & Asthma Care of Florida, Ocala, Florida, 2003.

Principal Investigator: “A Placebo-and Active-Controlled Efficacy and Safety Study of a Once-Daily Fixed Combination Tablet of Desloratadine 5 mg/Pseudoephedrine 120 mg (SCH 483[5/120]) in Subjects with Seasonal Allergic Rhinitis”, P01861, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2002.

Principal Investigator: “A Placebo-Controlled, Efficacy and Safety Study of Olopatadine Nasal Spray for the Treatment of Seasonal Allergic Rhinitis”, C-02-37, Alcon Research, Ltd., Allergy & Asthma Care of Florida, Ocala, Florida, 2002.

Principal Investigator: “A Phase IIIA, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study on the Efficacy and Safety of Fexofenadine HCl 180 mg Once Daily in Chronic Idiopathic Urticaria”, M016455A/4121, Aventis Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2002.

Principal Investigator: “A Prospective, Randomized, Double-Blind, Parallel-Group, Multi-Center, Placebo-Controlled Study, Comparing the Safety and Efficacy of 625 mg/day of Terbinafine Versus Placebo for 6 Weeks, in the Treatment of Chronic Rhinosinusitis”, CSFO327KUS13, Novartis Pharmaceuticals Corporation, Allergy & Asthma Care of Florida, Ocala, Florida, 2002.

Principal Investigator: “A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionate Aqueous Nasal Spray Versus FLONASE® Nasal Spray Versus Placebo Nasal Spray in Subjects with Seasonal Allergic Rhinitis”, RTRFLT-001, Roxane Laboratories, Incorporated, Allergy & Asthma Care of Florida, Ocala, Florida, 2002.

Principal Investigator: “A Multicenter, Double-Blind, Randomized, Parallel Group Study, 12 Weeks Treatment with 125 ug Roflumilast versus 250 ug Roflumilast versus Placebo in Patients with Asthma”, BY217/FK1 021, Byk Gulden Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease”, 091-050, Sepracor

Incorporated, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Multi-Center, Randomized, Single-Blind, Single Exposure, Cross-Over Evaluation of Subject Preference for Specific Sensory Attributes of Rhinocort® Aqua™ Versus Flonase® in Subjects with Allergic Rhinitis”, RAQ-1003, AstraZeneca, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Double Blind, Placebo-Controlled Study of Tecastemizole in Subjects with Seasonal Allergic Rhinitis and Concomitant Asthma”, 110-060, Sepracor, Incorporated, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Randomized, Study of Fexofenadine HCL 180 mg vs Ceterizine HCL 10 mg in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall Allergy Season”, M016455A/4122, Aventis Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Pilot Study of the Effect of Desloratadine on Nasal Congestion in a Subset of Subjects With Seasonal Allergic Rhinitis”, P02401, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy”, FAP30008, GlaxoWellcome Incorporated, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “Pilot Study To Investigate the Efficacy and Safety of a Combination of Desloratadine 5 mg QD Plus Pseudoephedrine 120 mg Sustained Release vs. A Combination of Loratadine 10 mg Plus Pseudoephedrine 240 mg QD Sustained Release vs. Placebo in Subjects With Seasonal Allergic Rhinitis”, P02299, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “Screening Protocol to Identify Subjects Who Exhibit Difficulty in Tolerating a High Dose of Pseudoephedrine”, P02315, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing The Effects of Ciclesonide Metered Dose Inhaler 50 ΦG/Day And 200 ΦG/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma”, Aventis XRP1526-B-343, Aventis Pharmaceuticals, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “Placebo-Controlled Efficacy and Safety Study of A Once-Daily PM and Twice Daily Regimens of Mometasone Furoate Administered via Dry Powder Inhaler in Subjects with Asthma Who Were Previously Maintained On Inhaled Corticosteroids”, P01545, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Long-term Treatment with Rhinocort® Aqua™ (budesonide) Nasal Spray in Children with Perennial Allergic Rhinitis”, 239 (SD-005-0414), AstraZeneca, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “An Observational Study of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR)”, Q2196n, Genentech, Incorporated, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Administered Via Dry Powder Inhaler in the Treatment of Asthma in children Previously Maintained on Inhaled Corticosteroids”, P01431, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 2001.

Principal Investigator: “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44 mcg BID and 88 mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 6 Months to 23 Months”, FMS30059, Glaxo Wellcome, Allergy & Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44 mcg BID and 88 mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24 Months to 47 Months”, FMS30058, Glaxo Wellcome, Allergy & Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “Efficacy and Safety of Two Formulations of SCH 483 5/240 mg, Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subjects with Seasonal Allergic Rhinitis”, P01884 Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “Efficacy and Safety of Combination Loratadine/Montelukast QD vs. Its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis”, P01997 Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Sub-Investigator: “A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine-Pseudoephedrine vs. Loratadine-Pseudoephedrine (Claritin-D® 12 Hour) vs. Placebo in the Treatment of Subjects Twelve Years and Older with Seasonal Allergic Rhinitis”, A3771001 Pfizer, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “A Study of the Effect of Desloratadine 5 mg and Pseudoephedrine 240 mg on Nasal Stuffiness in Subjects With Seasonal Allergic Rhinitis”, P01434, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “Efficacy and Safety of Desloratadine 5 mg Tablet in the Treatment of Subjects 12 to 17 Years of Age with Seasonal Allergic Rhinitis”, P01376, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg **DISKUS**† Inhaler BID versus Fluticasone Propionate 250 mcg **DISKUS**† Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma”, SAS40027, Glaxo Wellcome Incorporated, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250 mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone”, FPD40009, Glaxo Wellcome Incorporated, Allergy and Asthma Care of Florida, Ocala, Florida, 2000.

Principal Investigator: “A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics”, 120-01, Merck & Company, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Efficacy and Safety of SCH 34117 in Patients with Perennial Allergic Rhinitis”, P00218, Schering Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Safety and Efficacy of Roflumilast Versus Placebo in Subjects with Bronchial Asthma, A Double-Blind, Randomized Parallel Group Study”, By217/FK1 011, Byk Gulden Pharmaceuticals, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg BID Via the Diskus Inhaler Versus Oral Montelukast 10 mg QD in Adolescents and Adults with Persistent Asthma”, SAS40020, GlaxoWellcome Incorporated, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Efficacy and Safety of SCH 34117 plus Pseudoephedrine, BID, vs its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis”, P00362, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: Efficacy and Safety of SCH 34117 in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma”, P00214, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Efficacy and Safety in the Treatment of Chronic Idiopathic Urticaria (CIU) Subjects with SCH 34117”, P00221-12, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “A Multi-Center, Randomized, Double-Blind, Double Dummy, Parallel Group, 12 Week Active Control Comparison of Salmeterol/Fluticasone Propionate Combination Product (50/100 mcg BID) via the DISKUS Inhaler with Fluticasone Propionate (100 mcg BID) via the DISKUS Plus Oral Montelukast (10 mg QD) in Adults and Adolescents with Persistent Asthma Experiencing Symptoms on Inhaled Corticosteroid Therapy”, SAS40018, Glaxo Wellcome Incorporated, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler™ Device Versus Placebo in Pediatric Patients with Symptomatic Asthma”, 1343-BRON, 3M Pharmaceuticals, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Dose Ranging Study of Mometasone Furoate HFA 227 Nasal Aerosol in The Treatment of Patients with Seasonal Allergic Rhinitis”, C97-297, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Four-Week, Double-Blind, Safety and Efficacy Study of Beclomethasone Dipropionate Nasal Aerosol vs. Placebo in Children (age 3-5) with Perennial and/or Seasonal Allergic Rhinitis”, Protocol C98-641, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1999.

Principal Investigator: “Evaluation of Xopenex™ (levalbuterol HCl) Inhalation Solution in the Treatment of Asthma”, 051-902, SEPRACOR INC., Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Sub-Investigator: Novartis Pharmaceutical Corporation, “Randomized, Parallel-group, Open-Label Multicenter Clinical Study Comparing the Safety, Efficacy, Quality of Life and Socioeconomic Variables of Twice Daily Formoterol Powder (12 ug bid) to Twice Daily Salmeterol (50 ug bid) Administered for Six Months to Adult Subjects with Reversible Obstructive Airway Disease (ROAD)”, 073, Novartis Pharmaceutical Corporation, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “Safety Evaluation of Once Daily Dosing of Fexofenadine HCl 180 mg in Subjects with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma”, M016455/4092, Hoechst Marion Roussel, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “A Prospective, Randomized, Controlled, Multi-Center Clinical Trial of Ciprofloxacin 500 mg BID for 10 Days Versus Cefuroxime Axetil 250 mg BID for 10 Days for the Treatment of Patients with Acute Sinusitis”, D97-029, Bayer Pharmaceuticals, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “Placebo-Controlled efficacy and Safety Study of Mometasone Furoate dry Powder Inhaler (MF DPI) in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids”, C97-300, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “One-Year, Double-Blind Study of the Effects of Mometasone Furoate Dry Powder Inhaler (MF DPI) vs. Placebo on Growth of Children with Asthma”, C97-384, Schering-Plough Research Institute, Allergy & Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “One-Year, Open-Label Safety study of Mometasone Furoate Dry Powder Inhaler (FM DPI) and Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength) in Children with Asthma Previously Maintained on Inhaled Corticosteroids”, C97-385, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “A Multi-Center, Double-Blind Comparison of the Zafirlukast (Accolate) with Placebo in Pediatric Subjects with Mild to Moderate Asthma”, 9188IL/0150, Zeneca Pharmaceuticals, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “Long Term Safety of Mometasone Furoate HFA 227 Nasal Aerosol in Perennial Rhinitis”, C97-302-23, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “Efficacy and Safety of 800 mcg or 400 mcg of Mometasone Furoate Nasal Spray or Placebo in the Treatment of Acute Episodes of Sinusitis”, C97-251-54, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Principal Investigator: “A Two Year Study on the Effects of Mometasone Furoate Dry Powder Inhaler (MF-DPI) on Bone Density in Adult Asthmatics”, C97-210, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1998.

Sub-Investigator: “Placebo Controlled, Efficacy and Safety Study with Long-term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists”, Protocol C97-223, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “Placebo Controlled, Dose Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Compared to Beclomethasone Dipropionate (Vanceril DS) in the Treatment of Asthma in Patients Previously Maintained on Inhaled Corticosteroids”, Protocol C97-208, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “Montelukast Sodium vs Beclomethasone Dipropionate in Adult Asthmatics”, Protocol 070-00, Merck and Company, Inc., Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “Accolate™ (Zafirlukast) Clinical Experience and Pharmacoepidemiology Trial (ACCEPT), an Open Label, Noncomparative, Multi-Center Trial to Evaluate Accolate™ in Patients with Asthma”, Trial #9188US/0017, Zeneca Pharmaceuticals, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “Claritin-D 12 Hour and Guaifenesin (600 mg BID) Alone and in Combination vs Placebo in Patients with Seasonal Allergic Rhinitis and Cough”, Protocol C96-367, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “Efficacy and Safety of Mometasone Furoate Nasal Spray in the Prevention of Recurrences of Sinusitis”, Protocol C96-252, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “Placebo Controlled, Efficacy and Safety Study of Mometasone Furoate Dry Powder in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists”, Protocol C96-186, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “One-Year, Evaluator- Blind Safety Study of Mometasone Furoate Aqueous Nasal Spray vs Beclomethasone Dipropionate in Children (Ages 6-11) with Perennial Rhinitis”, Protocol C96-091, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1997.

Principal Investigator: “A Randomized, Double-Blind, Parallel Group Trial Evaluating Safety and Efficacy of Salmeterol 50 mcg BID and Fluticasone Propionate 100 mcg BID Individually and in Combination and Placebo in Subjects with Asthma”, Protocol SFCA3002, Glaxo Wellcome, Inc., Allergy and Asthma Care of Florida, Ocala, Florida, 1996.

Principal Investigator: “Dose Ranging Study of Mometasone Furoate Nasal Spray in the Treatment of Children (Ages 6-11) with Seasonal Allergic Rhinitis”, Protocol C95-161, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1996.

Principal Investigator: “Comparison of Fexofenadine vs Loratadine in Seasonal Allergic Rhinitis”, Protocol PJPR0054, Hoechst Marion Roussel, Inc., Allergy and Asthma Care of Florida, Ocala, FL, Allergy and Asthma Care of Florida, Ocala, Florida, 1996.

Principal Investigator: “A Multi-Center, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Oral Twice Daily Administration of SB 205312 in Pediatric Patients with Mild to Moderate Asthma”, Protocol 205312/084, SmithKline Beecham Pharmaceuticals, Allergy and Asthma Care of Florida, Ocala, Florida, Fall 1995.

Principal Investigator: “Placebo Controlled, Dose Ranging Study of Mometasone Furoate Pure Dry Powder in the Treatment of Asthma”, Protocol C94-127, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, Fall 1995.

Principal Investigator: “Safety and Efficacy of Mometasone Furoate Nasal Spray with the Addition of Loratadine vs Placebo in the Treatment of Seasonal Allergic Rhinitis”, Protocol C94-145, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, Spring 1995.

Principal Investigator: "Safety and Efficacy of Mometasone Furoate Nasal Spray vs Placebo in the Treatment of Elderly Patients with Perennial Rhinitis", Protocol C94-092, Schering-Plough Research Institute, Allergy and Asthma Care of Florida, Ocala, Florida, 1994. (Top Enroller Award)

Principal Investigator: "Randomized, Open Label, Comparative Study of Rhinocort® (Budesonide) Nasal Inhaler vs Beconase® (Beclomethasone Dipropionate) Inhalation Aerosol in the Treatment of Seasonal Allergic Rhinitis", Protocol #RPM-2439, Astra, Allergy and Asthma Care of Florida, Ocala, Florida, 1994.

Sub-Investigator: "Comparison of Oral Pulse Methotrexate with Placebo in Treatment of Severe Glucocorticosteroid Dependent Asthma", Division of Allergy & Clinical Immunology, University of South Florida, Tampa, Florida.

Sub-Investigator: "Immunochemical Characterization of *Myrica Cerifa* (Bayberry) Allergens", Division of Allergy & Clinical Immunology, University of South Florida, Tampa, Florida.

Sub-Investigator: "A Double-Blind Phase III Evaluation of Doxofylline, Theophylline, and Placebo in Patients with Chronic Reversible Asthma, #30, 722-302D", Roberts Pharmaceutical Corporation, 1994.

Sub-Investigator: "A Double-Blind, Randomized, Placebo Controlled, Trial of the Safety and Efficacy of Oral Bay x 1005 (100 mg bid vs 250 mg bid vs 500 mg bid vs Placebo for 6 Weeks) in Patients with Asthma", D93-024, Miles Pharmaceuticals, 1994.

Sub-Investigator: "A Multi-Center, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Doses of ZD2138 with Placebo Over 4 Weeks in Patients with Bronchial Asthma, 2138IL/0014", Zeneca Pharmaceuticals Group, 1994.

Sub-Investigator: "A Multi-Center, Double-Blind Efficacy Trial to Compare Accolate® (ICI 204, 219) Given at 160 mg/day with Placebo Over 13 Weeks to Subjects with Chronic Severe Asthma, 9188IL/0032", Zeneca Pharmaceuticals Group, 1993.

Sub-Investigator: "A Double-Blind, Parallel, Multi-Center Study of the Safety and Efficacy of Cetirizine and Clemastine vs Placebo in the Treatment of Seasonal Allergic Rhinitis in Children, L-0269", Pfizer, Inc., 1993.

Sub-Investigator: "A Multi-Center, Double-Blind Comparison of Accolate® (ICI 204, 219) with Cromolyn Sodium (Intal®, Fisons) in Mild to Moderate Asthmatic Patients, 9188IL/0057", Zeneca Pharmaceuticals Group, 1993.

Sub-Investigator: "A Multi-Center, Randomized, Double-Blind Study to Compare the Effect of Oral Doses of ICI 204, 219 with Placebo Over 13 Weeks in Patients with Mild to Moderate Asthma, 9188IL/0028", Zeneca Pharmaceuticals Group, 1993.

Sub-Investigator: "Randomized, Multi-Dose, Double-Blind, Comparison of Combivent® and Ventolin® in a Four Week Parallel Study in Patients with Chronic Obstructive Pulmonary Disease (COPD), 001029A", Boehringer Ingelheim Pharmaceuticals, Inc., 1993.

Sub-Investigator: "A Study of the Efficacy and Safety of Cefibuten (SCH 39720) vs Amoxicillin/Clavulanate in the Treatment of Acute Maxillary Sinusitis, C92-107", Schering-Plough Research Institute, 1993.

Sub-Investigator: "A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Four Weeks Treatment with Oral CP-80, 633 in Adult Patients with Chronic Mild to Moderate Asthma, Study 149-103", Pfizer, Inc., 1993.

Sub-Investigator: "A Multi-Center, Double-Blind, Placebo Controlled Trial of Accolate® (ICI 204, 219) in Mild to Moderate Asthmatic Patients Needing Chronic Treatment: 13 Weeks Efficacy and up to a Two Year Open Label Safety Extension (9188IL/0029)", Zeneca Pharmaceuticals Group, 1993.

Sub-Investigator: "A Multi-Center Study to Evaluate the Correlation Between Clinical Signs and Symptoms of Infection and the Pathogens Isolated in Patients with Acute Exacerbation of Chronic Bronchitis", G.D. Searle & Company, 1993.

Sub-Investigator: "Phase III Study of the Effects of Zileuton 600 mg QID in Patients with Moderate Asthma Completing Protocol M92-744", Abbott Laboratories, November 1992 to June 1994.

Sub-Investigator: "A Double-Blind, Parallel, Multi-Center Study of the Safety and Efficacy of Cetirizine 5 mg vs Cetirizine 10 mg vs Astemizole 10 mg in the Treatment of Seasonal Allergic Rhinitis", Pfizer, Inc., 1992.

Sub-Investigator: "A Multi-Center, Placebo Controlled Study to Compare the Efficacy and Safety of Hismanal-D® and Seldane-D® in the Treatment of Seasonal Allergic Rhinitis", Janssen Research Foundation, 1992.

Sub-Investigator: "Loracarbef® vs Ceftin® in Acute Exacerbation of Chronic Bronchitis, GHBA-412", Eli Lilly and Company and G.H. Besselaar Associates, May 1992 to June 1994.

Sub-Investigator: "Proventil Repetabs® for the Prevention of Nocturnal Symptoms of Asthma", Schering-Plough Research, July 1992 to June 1994.

Sub-Investigator: "Phase III Study of the Effects of Zileuton 400 mg QID and 600 mg QID and Placebo in Moderate Asthma, M91-685", Abbott Laboratories, June 1992 to June 1994.

Sub-Investigator: "Protocol to Compare the Effects of Hismanal-D®, Seldane-D®, and Placebo on Sleep and Nasal Congestion in Subjects with Seasonal Allergic Rhinitis", Janssen Research Foundation, 1992.

Sub-Investigator: "Conversion From Slo-Bid® to Theophylline Sprinkle Extended Release Capsules in Six to Twelve-Year-Olds, C91-032-05", Schering-Plough Research, 1992.

Sub-Investigator: "Treatment of AIDS-Associated Cachexia Patients with Halotestin® Tablets", The Upjohn Company, August 1991 to June 1994.

Sub-Investigator: "A Double-Blind, Randomized, Placebo Controlled Study to Determine the Relative Efficacy of Four Different Doses of Budesonide Turbuhaler® in Patients with Glucocorticosteroid Dependent Asthma, GHBA-165", Astra-Draco, August 1991 to June 1994.

Sub-Investigator: "A Double-Blind, Randomized, Placebo Controlled, Multi-Center, Steroid Sparing Study in Patients with Chronic Steroid Dependent Asthma, GHBA-166", Astra-Draco, August 1991 to June 1994.

Sub-Investigator: "A Pilot Study to Determine the Relative Efficacy and Safety of SCH-37370, Hydroxyzine and Placebo in Idiopathic Chronic Urticaria Patients", Schering-Plough Research, 1991.

Sub-Investigator: "Randomized, Double-Blind, Parallel Comparison of Atrovent® Nasal Spray 0.06% and 0.12% vs Placebo BID in Non-allergic Perennial Rhinitis", Boehringer-Ingelheim Pharmaceutical, 1991.

Sub-Investigator: "A Randomized, Double-Blind, Parallel Comparison of Atrovent® Nasal Spray 0.06% and 0.12% vs Placebo BID in Allergic Perennial Rhinitis", Boehringer-Ingelheim Pharmaceutical, 1991.

Sub-Investigator: "Randomized, Double-Blind, Placebo Controlled Study of Cetirizine in Seasonal Allergic Rhinitis", Pfizer, Inc., 1990.

Sub-Investigator: "New Approach to the Diagnosis and Treatment of House Dust Mite Allergy", Division of Allergy and Clinical Immunology, University of South Florida, May 1990 to September 1993.

Sub-Investigator: "Randomized, Double-Blind, Placebo Controlled Study of Cetirizine in Perennial Allergic Rhinitis", Pfizer, Inc., 1990.

